Back to results
US 6,312,661 B1Granted
Method for the detection and localization of ductal exocrine pancreas tumours
AssigneeMallinckrodt Inc.
InventorJean-Claude Reubi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMallinckrodt Inc.
InventorJean-Claude Reubi
Estimating the term…
The invention relates to a method of detecting and localizing malignant tumors and their metastases in tissues, which in healthy condition and in non-neoplastic conditions of chronic inflammation do not contain substantial quantities of neurotensin-receptors, in the body of a human being, which comprises: (i) administering to said being a composition comprising, in a quantity sufficient for external imaging, a radiolabelled peptide selected from the group consisting of neurotensin (NT), NT-receptor agonists. NT-receptor antagonists, NT analogues and NT derivatives; and thereupon (ii) subjecting said being to external imaging, by radioactive scanning or by magnetic resonance imaging, to determine the targeted sites in the body of said being. The invention further relates to a method for the therapeutic treatment of said malignant tumors by administration of the above-defined peptide, labelled for this purpose, and to the differential-diagnostic assessment and detection of a specific tumor type (i.e. ductal exocrine pancreatic carcinoma) of the pancreas. The invention also relates to a pharmaceutical composition to be used for detection, a pharmaceutical composition to be used for therapy and to a kit for preparing a radiopharmaceutical composition.
A method of detecting and localizing Ductal Exocrine Pancreas tumours and their metastases in tissues, which in healthy condition and in non-neoplastic conditions of chronic inflammation do not contain substantial quantities of neurotensin-receptors, in the body of a human being, which comprises (i) administering to said being a composition comprising, in a quantity sufficient for external imaging, a peptide selected from the group consisting of neurotensin (NT), NT-receptor agonists, NT-receptor antagonists, NT analogues and NT derivatives, said peptide being labelled with (a) a radioactive metal isotope selected from the group consisting of 99mTc, 203Pb, 67Ga, 68Ga, 72As, 111In, 113mIn, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn and 51Cr, or (b) with a paramagnetic metal atom selected from the group consisting of Cr, Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen isotope, selected from 123I, 124I, 125I, 131I, 75Br, 76Br, 77Br and 82Br, and thereupon (ii) subjecting said being to external imaging, by radioactive scanning or by magnetic resonance imaging, to determine the targeted sites in the body of said being in relation to the background activity, in order to allow detection and localization of said tumours in the body.
A method of intraoperatively detecting and localizing Ductal Exocrine Pancreas tumours in tissues, which in healthy condition and in non-neoplastic conditions of chronic inflammation do not contain substantial quantities of neurotensin-receptors, in the body of a human being, which comprises (i) administering to said being a composition comprising, in a quantity sufficient for detection by a gamma detecting probe, a peptide selected from the group consisting of neurotensin (NT), NT-receptor agonists, NT-receptor antagonists, NT analogues and NT derivatives, said peptide being labelled with 161Tb, 123I or 125I and thereupon (ii), after allowing the active substance to be bound and taken up in said tumours and after blood clearance of radioactivity, subjecting said being to a radioimmunodetection technique in the relevant area of the body of said being, by using a gamma detecting probe.
A method for the therapeutic treatment of Ductal Exocrine Pancreas tumours in tissues, which in healthy condition and in non-neoplastic conditions of chronic inflammation do not contain substantial quantities of neurotensin-receptors, in the body of a human being, which comprises administering to said being a composition comprising, in a quantity effective for combating or controlling tumours, a peptide selected from the group consisting of Neurotensin (NT), NT-receptor agonists, NT-receptor antagonists, NT analogues and NT derivatives, said peptide being labelled with an isotope selected irom the group consisting of 186Re, 188Re, 77As, 90Y, 67Cu, 169Er, 121Sn, 127Te, 142Pr, 143Pr, 198Au, 199Au, 161Tb, 109Pd, 165Dy, 149Pm 151Pm, 153Sm, 157Gd, 159Gd, 166Ho, 172Tm, 169Yb, 175Yb, 177Lu, 105Rh, 111Ag, 124I and 131I.
Dependencies are inferred from the claim text.